Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma. | Pathol Oncol Res | 2023 | 37006439 | PubTator, text mining | PubMed |
| Isolated anti-Ro52 identifies a severe subset of Sjögren's syndrome patients. | Front Immunol | 2023 | 37006271 | PubTator, text mining | PubMed |
| A single-cell atlas reveals shared and distinct immune responses and metabolic profiles in SARS-CoV-2 and HIV-1 infections. | Front Genet | 2023 | 36992700 | PubTator, text mining | PubMed |
| Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax. | Int J Mol Sci | 2023 | 36982875 | PubTator, text mining | PubMed |
| Physiological and Pathophysiological Roles of IgM Fc Receptor (FcµR) Isoforms. | Int J Mol Sci | 2023 | 36982860 | PubTator, text mining | PubMed |
| Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia. | Int J Mol Sci | 2023 | 36982555 | PubTator, text mining | PubMed |
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. | Int J Mol Sci | 2023 | 36982537 | PubTator, text mining | PubMed |
| Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression. | Cancer Gene Ther | 2023 | 36973425 | PubTator, text mining | PubMed |
| Characterisation of the immune repertoire of a humanised transgenic mouse through immunophenotyping and high-throughput sequencing. | Elife | 2023 | 36971345 | PubTator, text mining | PubMed |
| The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives. | Front Oncol | 2023 | 36968995 | PubTator, text mining | PubMed |
| Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. | BMC Pulm Med | 2023 | 36964522 | PubTator, text mining | PubMed |
Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Description of the Technical Performance, Clinical Utility, and Platform Comparison. | J Mol Diagn | 2023 | 36963483 | PubTator, text mining | PubMed |
| [Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 36948873 | PubTator, text mining | PubMed |
| Impaired Humoral Immunity Identified in Inactivated SARS-CoV-2 Vaccine Recipients without Anti-Spike RBD Antibodies. | Microbiol Spectr | 2023 | 36916970 | PubTator, text mining | PubMed |
| Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. | Nat Immunol | 2023 | 36914890 | PubTator, text mining | PubMed |
| Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease. | J Clin Med | 2023 | 36902559 | PubTator, text mining | PubMed |
| Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™. | Int J Mol Sci | 2023 | 36902040 | PubTator, text mining | PubMed |
| Emerging Therapies in CLL in the Era of Precision Medicine. | Cancers (Basel) | 2023 | 36900373 | PubTator, text mining | PubMed |
| Circular RNA Expression Signatures Provide Promising Diagnostic and Therapeutic Biomarkers for Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2023 | 36900344 | PubTator, text mining | PubMed |
| Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. | Cancers (Basel) | 2023 | 36900295 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=20